Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 53

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Disease risk factor+1

Not yet recruiting

Colchicine for Reducing Dependency and Vascular Events in Patients After Acute Intracerebral Hemorrhage

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Hamilton Health Sciences Corporation

Dementia Alzheimer's type

Not yet recruiting

Phase 2 Randomized Study of Mivelsiran in Adults with Early-Stage Down Syndrome-Associated Alzheimer’s Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:ALN-961583
  • Sponsor:Alnylam Pharmaceuticals Inc.

Epilepsy

Not yet recruiting

Safety and Tolerability of PTI5803 in Patients Aged 14 Years and Older With Drug‑Resistant Seizures Due to Focal Cortical Dysplasia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Sponsor:Panntherapi

Hereditary spastic paraplegia

Not yet recruiting

Study of Melpida with drug combination in patients with Hereditary Spastic Paraplegia Type 50 (SPG50)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Codeine Phosphate

Central nervous system neoplasm

Not yet recruiting

Safety of autologous NK cells with IL‑15 and CD45RA‑negative T cells with NKG2D CAR in children, adolescents and young adults with high‑grade brain tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Sponsor:Hospital Universitario La Paz

Ischaemic stroke

Not yet recruiting

Phase 2 Study of RADAMTS13 in Adults with Acute Ischemic Stroke

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

Cluster headache

Not yet recruiting

Sodium Oxybate for Nocturnal Cluster Headache Attacks in Adults with Chronic Cluster Headache: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Oxybate
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Brain injury

Not yet recruiting

Intranasal remestemcel therapy for newborns with hypoxic‑ischemic brain injury: a phase II placebo‑controlled trial

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Remestemcel
  • Sponsor:Universitair Medisch Centrum Utrecht

Migraine without aura

Not yet recruiting

Study of apremilast‑induced headache and migraine in women with migraine without aura

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Apremilast
  • Sponsor:Syddansk Universitet (University of Southern Denmark)

Severe myoclonic epilepsy of infancy

Not yet recruiting

Safety and Tolerability of Intrathecal ION337 in Patients with Dravet Syndrome

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Sponsor:Ionis Pharmaceuticals Inc.

Obesity+1

Not yet recruiting

Tirzepatide versus CPAP and Lifestyle Modification for Obstructive Sleep Apnea in Adults ≥ 65 years with Overweight or Obesity – Randomized Trial

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Tirzepatide
  • Sponsor:Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre

Parkinson's disease

Not yet recruiting

Study of inhaled levodopa versus oral levodopa plus benserazide for early‑morning OFF in Parkinson’s disease patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Levodopa
  • Sponsor:Region Hovedstaden

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.